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B-cell anomalies play a role in the pathogenesis of membranous nephropathy.
B-cell depletion with rituximab may therefore be noninferior to treatment with
cyclosporine for inducing and maintaining a complete or partial remission of proteinuria in patients with this condition.
METHODS

We randomly assigned patients who had membranous nephropathy, proteinuria of
at least 5 g per 24 hours, and a quantified creatinine clearance of at least 40 ml
per minute per 1.73 m2 of body-surface area and had been receiving angiotensinsystem blockade for at least 3 months to receive intravenous rituximab (two infusions, 1000 mg each, administered 14 days apart; repeated at 6 months in case of
partial response) or oral cyclosporine (starting at a dose of 3.5 mg per kilogram
of body weight per day for 12 months). Patients were followed for 24 months. The
primary outcome was a composite of complete or partial remission of proteinuria
at 24 months. Laboratory variables and safety were also assessed.
RESULTS

A total of 130 patients underwent randomization. At 12 months, 39 of 65 patients
(60%) in the rituximab group and 34 of 65 (52%) in the cyclosporine group had a
complete or partial remission (risk difference, 8 percentage points; 95% confidence
interval [CI], −9 to 25; P = 0.004 for noninferiority). At 24 months, 39 patients (60%)
in the rituximab group and 13 (20%) in the cyclosporine group had a complete or
partial remission (risk difference, 40 percentage points; 95% CI, 25 to 55; P<0.001 for
both noninferiority and superiority). Among patients in remission who tested positive
for anti–phospholipase A2 receptor (PLA2R) antibodies, the decline in autoantibodies
to anti-PLA2R was faster and of greater magnitude and duration in the rituximab
group than in the cyclosporine group. Serious adverse events occurred in 11 patients
(17%) in the rituximab group and in 20 (31%) in the cyclosporine group (P = 0.06).
CONCLUSIONS

Rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months. (Funded by Genentech and the Fulk Family Foundation;
MENTOR ClinicalTrials.gov number, NCT01180036.)
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embranous nephropathy is the
leading cause of nephrotic syndrome in
white adults. Spontaneous remission
occurs in approximately 30% of affected patients,
and among patients who continue to have nephrotic syndrome, end-stage renal disease develops in 40 to 50% over a period of 10 years.1 A
total of 70 to 80% of patients with membranous
nephropathy have circulating autoantibodies to
the phospholipase A2 receptor (PLA2R),2 and 1 to
3% have circulating antibodies to thrombospondin type-1 domain-containing 7A (THSD7A).3 In
the remaining patients, the target antigen is unknown. In patients with anti-PLA2R antibodies,
there is a tight correlation between antibody levels and disease activity, which suggests a causal
relationship.2,4-6
Initial therapy for patients with membranous
nephropathy is supportive7; immunosuppressive
therapy is recommended for patients with persistent nephrotic syndrome.7,8 A regimen of alternating glucocorticoids and cyclophosphamide9-11
is effective in 60 to 70% of patients but has been
associated with clinically significant toxic effects,
including hyperglycemia, myelosuppression, infections, infertility, and cancer.12-14 Calcineurin inhibitors, including cyclosporine, are effective and
are the preferred treatment for membranous
nephropathy in the United States and Canada.15
However, these agents are associated with a high
incidence of relapse after discontinuation and
with frequent side effects, including hypertension
and nephrotoxic effects.
B-cell dysfunction plays a role in the pathogenesis of membranous nephropathy.16 Cyclophosphamide has a profound but unselective B-cell–
depleting effect, leading to a reduced production
of nephrotoxic antibodies.17,18 More-selective B-cell
depletion with rituximab, therefore, appears to
be a promising approach.19 Multiple uncontrolled
studies with rituximab have shown a reduction in
proteinuria of 60 to 80% in the majority of patients for as long as 24 months after the initiation of immunosuppressive treatment.20-23 One
randomized trial compared rituximab with supportive therapy in patients with membranous nephropathy. Although there was no advantage with
rituximab with regard to the primary outcome at
6 months, follow-up over a period of 1 to 2 years
showed more remissions with rituximab than with
supportive therapy.24 We designed the Membranous Nephropathy Trial of Rituximab (MENTOR)
n engl j med 381;1

to investigate whether rituximab would be noninferior to cyclosporine in inducing and maintaining remission of proteinuria, regardless of
patients’ baseline anti-PLA2R status, for up to 24
months in patients with apparent primary membranous nephropathy.

Me thods
Trial Design and Oversight

This investigator-initiated, open-label, randomized, multicenter, noninferiority trial was conducted at 22 sites in North America. As described
previously,25 the trial was designed by the principal investigators and supported by Genentech
and the Fulk Family Foundation. Genentech also
donated rituximab; cyclosporine was purchased
at the usual market price. The funders had no
role in the trial design or conduct; the collection,
management, analysis, or interpretation of the
data; or in the preparation or review of the manuscript or the approval of the manuscript for submission. An independent data and safety monitoring board oversaw the trial (see the Supplementary
Appendix, available with the full text of this article at NEJM.org). Appropriately authorized ethics committees approved the trial at all participating sites. The manuscript was drafted and
written by the first and last authors, with input
as appropriate from the statistical team and the
investigators. The authors collected the data and
vouch for the completeness and accuracy of the
data and for the fidelity of the trial to the protocol (available at NEJM.org). The decision to submit the manuscript for publication was made by
the authors.
Participants

Patients with membranous nephropathy were
eligible if their diagnosis was confirmed by renal biopsy, with the biopsy sample examined by
light, immunofluorescence, and electron microscopy. Renal biopsy samples were centrally reviewed by the two principal investigators and two
renal pathologists. Patients also had to be 18 to
80 years of age, have proteinuria of more than 5 g
per 24 hours on average in two 24-hour urine
samples obtained within 14 days, have a decline
of less than 50% in proteinuria despite renin–
angiotensin system blockade for at least 3 months
before randomization, and have a stable quantified 24-hour creatinine clearance of at least 40 ml

nejm.org

July 4, 2019

37

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on July 18, 2019. For personal use only. No other uses without permission.
Copyright © 2019 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

per minute per 1.73 m2 of body-surface area. Full
eligibility criteria, including histologic results
from kidney biopsy, are provided in the Supplementary Appendix.
All patients received best-practice supportive
care that included blockers of the renin–angiotensin system, blood-pressure management targeting a value of less than 130/80 mm Hg, dietary sodium restriction to less than 4 g per day,
and dietary protein restriction to 0.8 to 1 g of
protein per kilogram of body weight per day
during at least the previous 3 months before
randomization. Patients who had not received
best-practice supportive care as part of their
routine treatment underwent a 3-month run-in
phase. If proteinuria remained at a level of at
least 5 g per 24 hours and the creatinine clearance was at least 40 ml per minute per 1.73 m2,
patients were randomly assigned in a 1:1 ratio to
receive rituximab or cyclosporine. The randomization schedule was computer-generated, stratified according to site, blocked with randomly
varied block sizes of two and four, and concealed with the use of a Web-based, locked central randomization system. All the patients provided written informed consent.
Interventions

Patients who were assigned to the rituximab
group received 1000 mg of intravenous medication (Rituxan, Genentech) on days 1 and 15. If
proteinuria was reduced from baseline by at least
25% at 6 months but there was not complete remission, a second course of rituximab was administered regardless of the CD19+ B-cell count.
If complete remission was observed at 6 months,
no second course was given. If proteinuria was
reduced by less than 25% by 6 months, the patient was considered to have treatment failure
and no further rituximab was administered (Fig.
S1 in the Supplementary Appendix).
Patients who were assigned to the cyclosporine
group received dose-adjusted cyclosporine (Neoral,
Novartis), starting at an oral dose of 3.5 mg per
kilogram per day, divided into two equal doses
given at 12-hour intervals. Target trough blood
levels of cyclosporine were 125 to 175 ng per milliliter.26 Blood levels were assessed every 2 weeks
until the target trough level was reached. If complete remission was observed at 6 months, cyclosporine was tapered and discontinued over a
2-month period. If proteinuria was reduced from
38
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baseline by less than 25% at 6 months, the patient was considered to have treatment failure
and cyclosporine was discontinued. If proteinuria was reduced by at least 25%, cyclosporine
was continued for an additional 6 months. At
the end of 12 months, cyclosporine was tapered
by one third of the maintenance dose monthly
and discontinued after 2 months. A persistent
and otherwise unexplained increase in the serum
creatinine level of more than 30% was managed
by dose reduction as described previously.25 If the
creatinine level did not fall to baseline values despite dose reductions, cyclosporine was discontinued and the patient was considered to have
treatment failure.
Outcomes and Follow-up

The primary clinical outcome was the composite
of complete or partial remission at 24 months.
Secondary clinical outcomes included the composite of complete or partial remission at 6, 12,
and 18 months; complete remission at 6, 12, 18,
and 24 months; time to treatment failure up to
24 months; end-stage renal disease; and adverse
events. Continuous secondary outcomes, including anti-PLA2R levels, quality of life as assessed
with the modified Kidney Disease Quality of Life
Short Form (KDQOL-SF), version 1.3,27 proteinuria, and creatinine clearance, were systematically
recorded only up to the occurrence of treatment
failure.
Complete remission was defined as proteinuria of no more than 0.3 g per 24 hours and a
serum albumin level of at least 3.5 g per deciliter. Partial remission was defined as a reduction
in proteinuria of at least 50% from baseline plus
final proteinuria between 0.3 g and 3.5 g per 24
hours regardless of creatinine clearance or the
serum albumin level. We defined no response as
no reduction in proteinuria of at least 25% from
baseline. Relapse was defined as the development of proteinuria of more than 3.5 g per 24
hours after a complete or partial remission. Endstage renal disease was defined as a creatinine
clearance of no more than 15 ml per minute, the
initiation of dialysis, or renal transplantation. A
list of outcomes and definitions is provided in
the Supplementary Appendix.
The run-in phase included visits at −3 months
and at week 0, when patients underwent randomization and treatment was initiated. Subsequent visits for patients who had undergone ran-
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domization were scheduled at 1, 3, 6, 9, and 12
months (treatment period) and at 18 and 24
months (observation period). Proteinuria and
creatinine clearance were estimated with the use
of quantified 24-hour urine samples. Critical laboratory values, including 24-hour urinary protein
and creatinine, serum creatinine, and anti-PLA2R
antibody levels as measured by enzyme-linked
immunosorbent assay (ELISA),28 were assessed
centrally (Section F in the Supplementary Appendix). Patients were considered to be anti-PLA2R–
positive if the baseline antibody level was more
than 40 U per milliliter.
Statistical Analysis

We calculated that a sample of 63 patients per
group would provide the trial with 80% power to
detect noninferiority regarding the primary outcome at a one-sided alpha of 0.025 (equivalent to
a two-sided alpha of 0.05) and a noninferiority
margin of 15 percentage points on an absolute
risk-difference scale, assuming that 55% of the
patients in the rituximab group and 45% of those
in the cyclosporine group had a complete or partial remission at 24 months. The analysis of the
primary composite outcome was performed in
the intention-to-treat population with the use of
a stepwise approach to control the family-wise
type I error, first testing the noninferiority of rituximab and then testing the superiority of rituximab
if the noninferiority test was significant. An additional, prespecified noninferiority analysis of the
primary outcome was performed in the per-protocol population. In both the intention-to-treat
analysis and the per-protocol analysis, noninferiority would be claimed if the lower limit of the
two-sided 95% confidence interval for the risk
difference was not below −15 percentage points.
A noninferiority analysis of the secondary outcome
of complete or partial remission at 12 months in
the intention-to-treat population was prespecified in the statistical analysis plan. The analysis
used a prespecified Bonferroni correction, which
allowed for this outcome to be tested in addition
to the primary outcome at a one-sided alpha
level of 0.0125. One-sided P values for noninferiority were calculated from z tests against the
noninferiority margin, with calculation of the
standard error in a generalized linear model.
An extended description of the statistical methods, including subgroup analyses, is provided in
the Supplementary Appendix. Since the widths
n engl j med 381;1

of 95% confidence intervals for secondary outcomes were not adjusted for multiple comparisons,
these intervals should not be used for inferences
about treatment effects. All the analyses were
performed with the use of Stata software, version 14.2 (StataCorp).

R e sult s
Patients

From March 2012 through September 2015, a
total of 182 patients were screened, 130 were
enrolled, and 65 were randomly assigned to each
group (Fig. S2 in the Supplementary Appendix).
The mean age of the patients was 52 years, 100
patients (77%) were men, and 96 patients (74%)
were anti-PLA2R–positive (Table 1). One patient
who was randomly assigned to the rituximab
group was anti-THSD7A–positive.
One patient who was assigned to the rituximab group withdrew consent after randomization and before treatment began; the remaining
patients received at least one dose of the assigned intervention. A total of 2 patients (3%) in
the rituximab group and 11 (17%) in the cyclosporine group discontinued the intervention (difference, 14 percentage points; 95% confidence
interval [CI], 4 to 24). Patients who had a decrease in proteinuria of less than 25% and were
classified as having treatment failure at 6 months
tended to have higher anti-PLA2R levels at baseline and 6 months, were less likely to have an
immunologic response, and had a lower serum
albumin level at 6 months than patients who had
a decrease in proteinuria of 25% or more (Tables
S1 through S3 in the Supplementary Appendix).
CD19+ B-cell counts in the rituximab group and
serum trough cyclosporine levels in the cyclosporine group are shown in Figures S3 and S4,
respectively, in the Supplementary Appendix. Follow-up was complete for 63 patients (97%) in the
rituximab group and for 61 (94%) in the cyclosporine group.
Clinical Outcomes

A total of 39 patients (60%) in the rituximab
group and 13 (20%) in the cyclosporine group
had a primary composite outcome of complete or
partial remission at 24 months (risk difference,
40 percentage points; 95% CI, 25 to 55) (Fig. 1).
Tests for noninferiority in the intention-to-treat
and per-protocol populations (Table S4 in the
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Table 1. Characteristics of the Patients at Baseline.*
Characteristic

Rituximab
(N = 65)

Cyclosporine
(N = 65)

Age — yr

51.9±12.6

52.2±12.4

47 (72)

53 (82)

Systolic

125.7±14.8

123.3±13.4

Diastolic

74.7±10.1

76.5±9.8

1.7±0.1

1.7±0.1

Male sex — no. (%)
Blood pressure — mm Hg

Height — m
Weight — kg

96±23

90±20

Body-mass index†

31.8±6.3

29.3±5.6

History of immunosuppressive
therapy — no. (%)

19 (29)

20 (31)

Low-density lipoprotein

114.1±57.7

122.3±63.0

Total

145.1±61.6

144.8±69.8

Cholesterol — mg/dl

Anti-PLA2R — U/ml
Median
Interquartile range
Anti-PLA2R positive — no. (%)‡

409

413

163–834

206–961

50 (77)

46 (71)

2.5

2.5

Serum albumin — g/dl
Median
Interquartile range

2.1–2.9

2.1–2.9

Serum creatinine — mg/dl

1.3±0.4

1.3±0.4

Urinary protein — g/24 hr
Median
Interquartile range
Urinary creatinine — g/24 hr
Creatinine clearance —
ml/min/1.73 m2
Protein:creatinine§

8.9

8.9

6.8–12.3

6.7–12.9

1.7±0.5

1.8±0.6

84.9±29.8

87.4±34.4

6.2±2.6

6.2±3.3

*	Plus–minus values are means ±SD. To convert values for cholesterol to milli‑
moles per liter, multiply by 0.02586. To convert values for creatinine to micro‑
moles per liter, multiply by 88.4. Anti-PLA2R denotes anti–phospholipase A2
receptor autoantibody.
†	The body-mass index is the weight in kilograms divided by the square of the
height in meters.
‡	Patients were considered to be anti-PLA2R–positive if the value was more
than 40 U per milliliter.
§	Protein and creatinine values were measured in milligrams.

Supplementary Appendix) and the subsequent test
for superiority in the intention-to-treat population
were all significant at a P value of less than 0.001.
The secondary noninferiority analysis of the composite of complete or partial remission at 12
months was significant (P = 0.004). Table 2 pres40
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ents data regarding the composite of complete or
partial remission at time points from 6 months to
24 months.
The treatment effect of rituximab as compared with cyclosporine appeared to be consistent across subgroups defined according to age,
proteinuria, anti-PLA2R antibody status, and
history of immunosuppressive therapy at baseline. However, a test for interaction with sex indicated a more pronounced benefit of rituximab
in women than in men (P<0.001 for interaction),
which was probably due to baseline imbalances
in anti-PLA2R levels (Fig. S5 and Table S5 in the
Supplementary Appendix). The interaction disappeared after adjustment for anti-PLA2R levels
at baseline (Table S6 in the Supplementary Appendix).
At 24 months, 23 patients (35%) in the rituximab group and none of the patients in the cyclosporine group had a complete remission (risk
difference, 35 percentage points; 95% CI, 24 to 47)
(Table S7 in the Supplementary Appendix). Of
these patients, 18 were positive for anti-PLA2R
antibodies at baseline and all were antibodynegative at 24 months.
A total of 26 patients (40%) in the rituximab
group and 52 (80%) in the cyclosporine group
had treatment failure by 24 months (hazard ratio, 0.34; 95% CI, 0.21 to 0.54) (Fig. 2). Figure S6
in the Supplementary Appendix shows time-toevent curves for complete or partial remission
during the 12-month treatment period; patients
in the cyclosporine group tended to have remission earlier, with a later catch-up in patients in
the rituximab group. At the end of the treatment
period, 39 patients (60%) in the rituximab group
and 34 (52%) in the cyclosporine group had a
complete or partial remission (hazard ratio for
response, 0.85; 95% CI, 0.55 to 1.32). Figure S7
in the Supplementary Appendix presents timeto-event curves for treatment failure during the
12-month observation period among these 39
and 34 patients who were in remission at the
end of treatment period. A total of 2 of the 39
patients (5%) in the rituximab group and 21 of
the 34 patients (62%) in the cyclosporine group
had treatment failure during this period (hazard
ratio, 0.05; 95% CI, 0.01 to 0.23). Table S8 in the
Supplementary Appendix shows the cumulative
numbers of patients with treatment failure at
months 6 to 24, with pronounced between-group
differences at 18 months and 24 months.
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Evaluation Time Point

Rituximab
(N=65)

Cyclosporine
(N=65)

no. with complete or
partial remission (%)
End of treatment period
at 12 mo
End of follow-up at 24 mo

39 (60)

34 (52)

39 (60)

13 (20)

Risk Difference P Value for P Value for
(95% CI)
Noninferiority Superiority
Noninferiority
margin

−45

−30

−15

0

percentage points

15

30

45

8 (−9 to 25)

0.004

—

40 (25 to 55)

<0.001

<0.001

60

Rituximab Noninferior to Cyclosporine
Rituximab Superior to Cyclosporine

Figure 1. Composite Outcome of Complete or Partial Remission at 12 and 24 Months.
Point estimates and two-sided 95% confidence intervals are shown for the treatment effect, defined as the risk difference for complete
or partial remission between groups in the intention-to-treat analysis. The noninferiority margin for rituximab as compared with cyclo‑
sporine was −15 percentage points. The lower end of the two-sided 95% confidence interval of the risk difference in the secondary com‑
posite of complete remission or partial remission at 12 months was above −15 percentage points, and the P value for noninferiority of
0.004 was significant, which met the prespecified alpha level of a P value of less than 0.0125 after Bonferroni correction. Per the statisti‑
cal analysis plan, no test for superiority was performed for the secondary outcome of complete or partial remission at 12 months. The
lower limit of the two-sided 95% confidence interval for the risk difference in the primary composite outcome of complete remission or
partial remission at 24 months was above 0 percentage points; both the criterion for noninferiority and the criterion for superiority of
rituximab were met at a P value of less than 0.001, which met the prespecified alpha levels specified for noninferiority (P<0.025) and su‑
periority (P<0.05). P values for noninferiority are one-sided, and the P value for superiority is two-sided.

Table 2. Composite Outcome of Complete or Partial Remission at 6 to 24 Months.*
Time from Randomization

Rituximab

Cyclosporine

no. of patients with remission/total no. (%)

Risk Difference (95% CI)
percentage points

Intention-to-treat population
6 mo

23/65 (35)

32/65 (49)

−14 (−31 to 3)

12 mo

39/65 (60)

34/65 (52)

8 (−9 to 25)

18 mo

40/65 (62)

15/65 (23)

38 (23 to 54)

24 mo

39/65 (60)

13/65 (20)

40 (25 to 55)

6 mo

22/63 (35)

32/63 (51)

−16 (−33 to 1)

12 mo

38/63 (60)

33/63 (52)

8 (−9 to 25)

Per-protocol population

18 mo

39/63 (62)

15/63 (24)

38 (22 to 54)

24 mo

39/63 (62)

13/63 (21)

41 (26 to 57)

*	The intention-to-treat population included all the patients who underwent randomization, and the per-protocol popula‑
tion included all the patients who received a full course of trial medications, defined as at least one completed 6-month
treatment cycle, according to the protocol. The primary outcome was the composite of complete or partial remission at
24 months. The primary noninferiority analysis and the superiority analysis of the primary outcome at 24 months were
performed in the intention-to-treat population, and an additional noninferiority analysis of the primary outcome at 24
months was performed in the per-protocol population. Because the widths of the 95% confidence intervals for second‑
ary outcomes were not adjusted for multiple comparisons, these intervals should not be used for inference about treat‑
ment effects.

of 8.79 g per 24 hours at baseline to 0.30 g per
In the 39 patients who were in remission 24 24 hours at 24 months, and in the 13 patients who
months after the initiation of rituximab therapy, were in remission 24 months after the initiation
proteinuria had decreased from a geometric mean of cyclosporine therapy, proteinuria had decreased
Laboratory Outcomes and Quality of Life
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Cumulative Incidence (%)

100

75

Rituximab

50

25
Cyclosporine
0

0

6

12

18

24

Months since Randomization
No. at Risk
Rituximab
Cyclosporine

65
65

59
56

48
42

48
20

44
13

Figure 2. Time to Treatment Failure.
Shown are Kaplan–Meier estimates of the time to treatment failure. Patients
were considered to have treatment failure if they had reduction in protein‑
uria of less than 25% from baseline at 6 months, had a relapse, had a pre‑
mature termination of the protocol-specified treatment schedule before
12 months because of disease activity or adverse event, used an immuno‑
suppressive medication other than the trial medication for the treatment
of membranous nephropathy before 12 months, used any immunosuppres‑
sive medication for the treatment of membranous nephropathy after
12 months and before 24 months, or did not meet the criteria for a com‑
plete or partial remission at 24 months. Patients who were lost to follow-up
at 24 months were considered to have had treatment failure unless they
were found to have had a complete or partial remission at their 18-month
visit. A test of the proportional-hazards assumption based on Schoenfeld
residuals showed a P value of 0.06. A time-by-treatment interaction that
was based on a cutoff at 1 year to distinguish between the treatment peri‑
od up to 12 months and the subsequent follow-up from month 13 through
month 24 was positive (ratio of hazard ratios, 0.22; 95% CI, 0.09 to 0.55;
P = 0.001 for interaction), with hazard ratios of 0.68 (95% CI, 0.36 to 1.26)
for the period up to 12 months and 0.15 (95% CI 0.07 to 0.30) for the peri‑
od between 13 and 24 months. After the inclusion of the interaction term,
the overall test of the proportional-hazards assumption was negative
(P = 0.17).

of

m e dic i n e

ences of 26 ml per minute per 1.73 m2 (95% CI,
17 to 35) at 12 months and of 18 ml per minute
per 1.73 m2 (95% CI, 5 to 31) at 24 months. Details are provided in Figures S8 and S9 and Tables S9 and S10 in the Supplementary Appendix.
The decline in anti-PLA2R antibody levels was
faster and of greater magnitude and duration in
anti-PLA2R–positive patients in remission in the
rituximab group than in those in the cyclosporine
group and was accompanied by a greater decline
in proteinuria. The anti-THSD7A–positive patient
who had been assigned to the rituximab group was
anti-THSD7A–negative from 3 months onward and
then had a partial remission at 9 months and a
complete remission at 12 months, which was
maintained until 24 months. Details are provided
in Figure S10 and Tables S11 through S13 in the
Supplementary Appendix.
Table S14 in the Supplementary Appendix
presents selected quality-of-life subscales in patients with remission of proteinuria at 6, 12, and
24 months. There was little evidence of betweengroup differences, except in the symptom or problem list at 6 months and the mental health composite at 12 months.
Adverse Events

The incidence of adverse events was similar in
the rituximab group and the cyclosporine group
(71% and 78% of patients, respectively). The incidence of adverse events of grade 3 or higher
was 52% in the rituximab group and 68% in the
cyclosporine group, and the incidence of serious
adverse events was 17% and 31%, respectively
(Table 3). A total of seven patients (11%) discontinued cyclosporine because of adverse events
(Table S15 in the Supplementary Appendix). Increased serum creatinine levels and gastrointestinal events were more common with cyclosporine,
whereas pruritus and infusion-related reactions
were more frequent with rituximab. End-stage
renal disease developed in one patient in the cyclosporine group. No cancers or deaths occurred
during the trial. Tables S16 through S32 and
Figure S11 in the Supplementary Appendix present
additional analyses of efficacy and safety outcomes.

from 9.46 g per 24 hours to 1.02 g per 24 hours
(between-group difference at 24 months, −0.72
g per 24 hours; 95% CI, −0.86 to −0.47). Blood
pressure remained stable during treatment with
rituximab but increased with cyclosporine treatment, with differences at 12 months of −10.7
mm Hg (95% CI, −17.2 to −4.1) in the systolic
blood pressure and −6.6 mm Hg (95% CI, −10.4
to −2.7) in the diastolic blood pressure. There
was little evidence of between-group differences
at 18 and 24 months. The mean creatinine clearDiscussion
ance in patients in remission was higher in the
rituximab group than in the cyclosporine group We found that rituximab was noninferior to cyat all time points, with between-group differ- closporine in inducing proteinuria remission at
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Table 3. Adverse Events.
Event

Rituximab (N = 65)

Any adverse event

Cyclosporine (N = 65)

P Value*

Patients

Events

Patients

Events

no. (%)

no. of events (rate
per 100 patients)

no. (%)

no. of events (rate
per 100 patients)

46 (71)

179 (275)

51 (78)

218 (335)

0.31

Grade ≥3

11 (17)

14 (22)

23 (35)

27 (42)

0.02

Grade <3

44 (68)

165 (254)

45 (69)

191 (294)

0.85

11 (17)

13 (20)

20 (31)

22 (34)

0.06

Serious adverse event
Fatal

0

0

0

0

1.00

11 (17)

13 (20)

20 (31)

22 (34)

0.06

Hypertension

0

0

5 (8)

6 (9)

0.06

Hyperkalemia

1 (2)

1 (2)

4 (6)

12 (18)

0.37

Gastrointestinal pain

1 (2)

2 (3)

9 (14)

9 (14)

0.02

Gingival event

1 (2)

1 (2)

4 (6)

4 (6)

0.37

Nausea or vomiting

2 (3)

4 (6)

9 (14)

15 (23)

0.03

Chills

1 (2)

1 (2)

5 (8)

5 (8)

0.21

Edema

4 (6)

5 (8)

5 (8)

6 (9)

1.00

Fatigue

5 (8)

6 (9)

8 (12)

8 (12)

0.38

Nonfatal
Adverse event occurring in ≥4 patients

Influenza-like symptoms

6 (9)

8 (12)

3 (5)

3 (5)

0.49

Infusion-related reaction

16 (25)

22 (34)

0

0

<0.001

Gastrointestinal infection

4 (6)

4 (6)

4 (6)

4 (6)

1.00

Pneumonia

1 (2)

1 (2)

6 (9)

6 (9)

0.12

Other respiratory tract infection

9 (14)

12 (18)

9 (14)

10 (15)

1.00

Skin infection

4 (6)

5 (8)

0

0

0.12

Muscle cramps

6 (9)

9 (14)

4 (6)

5 (8)

0.74

Myalgia

4 (6)

4 (6)

6 (9)

8 (12)

0.74

Pain

2 (3)

3 (5)

4 (6)

7 (11)

0.68

Dizziness

2 (3)

3 (5)

4 (6)

5 (8)

0.68

Headache

4 (6)

5 (8)

7 (11)

8 (12)

0.34

Paresthesia or dysesthesia

2 (3)

2 (3)

4 (6)

5 (8)

0.68

Anxiety or depression

1 (2)

1 (2)

4 (6)

6 (9)

0.37

Increased creatinine level†

4 (6)

5 (8)

15 (23)

17 (26)

0.01

Cough

7 (11)

9 (14)

2 (3)

4 (6)

0.16

Dyspnea

2 (3)

2 (3)

3 (5)

3 (5)

1.00

Pruritus

7 (11)

8 (12)

0

0

0.01

*	P values are for the difference in proportions of patients having a specific type of event. P values were not adjusted for multiple comparisons.
†	End-stage renal disease developed in one patient in the cyclosporine group.

12 months and was superior in maintaining
long-term proteinuria remission up to 24 months
in patients with membranous nephropathy who
were at high risk for progressive disease.7 The
n engl j med 381;1

superiority of rituximab at 24 months appeared
to be driven by the significantly lower incidence
of relapse in the rituximab group than in the
cyclosporine group during the observation peri-
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od at months 13 to 24. The observed response at
24 months was close to the percentage that had
been assumed in the power analysis for rituximab but was less than half the assumed percentage for cyclosporine. The lower-than-anticipated response in the cyclosporine group may be
due to the inclusion of patients who had more
severe proteinuria than did the patients in our
previous trial.13 The decline in proteinuria was
more pronounced in patients who had a complete or partial remission with rituximab than in
those in the cyclosporine group who had a complete or partial remission, and 23 patients
treated with rituximab had a complete remission
at 24 months, as compared with none of the
patients treated with cyclosporine — a finding
that suggests more frequent and more sustained
remissions with rituximab than with cyclosporine. Remission of proteinuria is a recognized
surrogate marker for long-term outcome in patients with membranous nephropathy.29 A recent
study involving patients with membranous nephropathy showed that the longer the remission,
the greater the improvement in renal survival
— a finding that emphasizes the value of partial
remission and complete remission of proteinuria
as surrogates for long-term outcome in patients
with membranous nephropathy.30
Adverse events were common and similar in
the two groups, but serious events were slightly
less frequent with rituximab than with cyclosporine — findings that are consonant with recent
data.14 Renal function was worse after cyclosporine therapy than after rituximab therapy; the
reduction in renal function after cyclosporine
use was only partially explained by reversible
hemodynamic effects during active treatment.
Residual kidney dysfunction persisted after the
discontinuation of cyclosporine therapy, which
suggests that chronic cyclosporine nephrotoxicity, a known negative effect of cyclosporine, may
have played a role.
Finally, between-group differences in complete or partial remission appeared to be more
pronounced in women than in men — a finding
that is probably explained by confounding due to
baseline imbalances in anti-PLA2R levels. Antibody suppression occurred earlier and was more
complete and sustained, persisting throughout
the second year of the trial, in anti-PLA2R–positive patients who were treated with rituximab
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than in anti-PLA2R–positive patients who were
treated with cyclosporine. The immunologic response to rituximab preceded the clinical response, a pattern that consistently emerges from
the trials in membranous nephropathy that have
shown the dynamics of anti-PLA2R antibody
levels in relation to clinical variables.4,6,20 Extensive immunologic damage requires prolonged
podocyte remodeling before the architecture and
function of the glomerular filtration barrier are
restored, and such damage may explain the delay between immunologic response and decline
in proteinuria.
The infrequent intravenous administration of
rituximab, as compared with twice-daily oral
cyclosporine, resulted in better adherence to
therapy. Although the initial treatment costs are
substantially higher with rituximab than with
cyclosporine, this factor needs to be weighed
against the prolonged benefits, higher quality of
remission, better preservation of kidney function, and lower incidence of relapse with rituximab. A recent analysis of the cost-effectiveness
of treating membranous nephropathy with alternating glucocorticoids and cyclophosphamide,
as compared with rituximab, showed that despite
initially higher costs of rituximab, the overall cost
was lower because of the prolonged remission
that was obtained with rituximab.31 The limited
overall incidence of remission of 50 to 60% may
be an underestimation of the true effect of rituximab since, as shown in other studies involving
patients who had a response to rituximab, proteinuria decline is gradual and the nadir may not
be reached until 36 months after the initiation
of treatment.20
Given the complex immunosuppressive treatment regimens and the cost involved, it did not
seem feasible in our trial for patients and therapists to be unaware of the treatment assignments,
which could have affected the treatment of the
patient and the assessment of disease status.
However, the definition of the primary outcome
was based on objective laboratory values measured by personnel who were unaware of group
assignments; thus, lack of blinding seems to be
an unlikely explanation for the magnitude of the
observed between-group difference at 24 months.
We cannot rule out the possibility that longer
treatment or follow-up of patients who did not
have a decrease in proteinuria of at least 25% at
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6 months might eventually have increased the
percentage of patients with a response. However,
in view of the symmetric pattern that was observed
at 6 months in patients assigned to the rituximab group and those assigned to the cyclosporine group, we speculate that it is unlikely that a
hypothetical change in protocol, with longer treatment and follow-up for patients with a decrease in
proteinuria of less than 25% at 6 months, would
have changed the overall conclusions.
Another limitation of our trial is that laboratory outcomes and quality of life were systematically recorded only up to the occurrence of
treatment failure. Therefore, those outcomes were
analyzed only in patients who had remission at
each time point. Although that approach allowed
comparisons of the quality of remission between
groups, the design did not allow us to explore
the effect of the originally assigned treatment
strategy on laboratory outcomes and quality of life
in the intention-to-treat population. It is possible
that between-group differences in KDQOL-SF
quality-of-life scores in the intention-to-treat
population would have been considerably more
pronounced, but studies involving patients with
membranous nephropathy that could confirm
or refute this hypothesis have been limited. The
observed modest between-group differences in
the KDQOL-SF mental health composite in patients who were in remission at 12 months, if

confirmed, might relate to differences in perceived intrusiveness or effect of the two treatments on daily life, but their clinical relevance
remains unclear.
Since the CD19+ B-cell counts remained low at
12 months, we cannot rule out a residual therapeutic effect of rituximab beyond this time period. However, in our two previous studies, CD19+
B-cell counts at 12 months showed no relation
to proteinuria response.21,22 We also acknowledge
that using a lower cutoff value for the ELISA,
performing Western blot, or detecting anti-PLA2R
antibodies by means of serum immunofluorescence could have resulted in more patients who
were considered to be PLA2R–positive.32
In conclusion, rituximab was noninferior to
cyclosporine in inducing proteinuria remission
at 12 months and was superior in maintaining
long-term proteinuria remission up to 24 months
in patients with membranous nephropathy who
were at high risk for progressive disease.
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